ROZLYTREK (entrectinib) is an innovative FDA-approved treatment designed for patients with ROS1-positive metastatic non-small cell lung cancer (mNSCLC) and select NTRK fusion-positive solid tumors. By targeting specific genetic mutations, ROZLYTREK offers a precision therapy that can significantly improve outcomes for those diagnosed with these difficult-to-treat cancers. The medication is suitable for adult patients with ROS1-positive mNSCLC, and also extends its benefits to pediatric patients aged over one month who are suffering from NTRK gene fusion-positive solid tumors.

ROZLYTREK is part of a broader commitment to advancing oncology solutions, providing essential resources such as prescribing information, dosing guidelines, and safety information for healthcare providers and caregivers. The brand emphasizes the importance of genetic testing in identifying eligible patients for this targeted therapy, and it also offers financial assistance options to help alleviate the burden of treatment costs. ROZLYTREK exemplifies the push toward personalized medicine in oncology, making precision treatment a reality for those in need.